<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34016561</PMID><DateCompleted><Year>2021</Year><Month>07</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2213-1582</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>NeuroImage. Clinical</Title><ISOAbbreviation>Neuroimage Clin</ISOAbbreviation></Journal><ArticleTitle>Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.</ArticleTitle><Pagination><StartPage>102672</StartPage><MedlinePgn>102672</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102672</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nicl.2021.102672</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2213-1582(21)00116-9</ELocationID><Abstract><AbstractText>Ibudilast (MN-166) is an inhibitor of macrophage migration inhibitory factor (MIF) and phosphodiesterases 3,4,10 and 11 (Gibson et al., 2006; Cho et al., 2010). Ibudilast attenuates CNS microglial activation and secretion of pro-inflammatory cytokines (Fujimoto et al., 1999; Cho et al., 2010). In vitro evidence suggests that ibudilast is neuroprotective by suppressing neuronal cell death induced by microglial activation. People with ALS have increased microglial activation measured by [<sup>11</sup>C]PBR28-PET in the motor cortices. The primary objective is to determine the impact of ibudilast on reducing glial activation and neuroaxonal loss in ALS, measured by PBR28-PET and serum Neurofilament light (NfL). The secondary objectives included determining safety and tolerability of ibudilast high dosage (up to 100&#xa0;mg/day) over 36&#xa0;weeks. In this open label trial, 35 eligible ALS participants underwent ibudilast treatment up to 100&#xa0;mg/day for 36&#xa0;weeks. Of these, 30 participants were enrolled in the main study cohort and were included in biomarker, safety and tolerability analyses. Five additional participants were enrolled in the expanded access arm, who did not meet imaging eligibility criteria and were included in the safety and tolerability analyses. The primary endpoints were median change from baseline in (a) PBR28-PET uptake in primary motor cortices, measured by standard uptake value ratio (SUVR) over 12-24&#xa0;weeks and (b) serum NfL over 36-40&#xa0;weeks. The secondary safety and tolerability endpoints were collected through Week 40. The baseline median (range) of PBR28-PET SUVR was 1.033 (0.847, 1.170) and NfL was 60.3 (33.1, 219.3) pg/ml. Participants who completed both pre and post-treatment scans had PBR28-PET SUVR median(range) change from baseline of 0.002 (-0.184, 0.156) , P&#xa0;=&#xa0;0.5 (n&#xa0;=&#xa0;22). The median(range) NfL change from baseline was 0.4&#xa0;pg/ml (-1.8, 17.5), P&#xa0;=&#xa0;0.2 (n&#xa0;=&#xa0;10 participants). 30(86%) participants experienced at least one, possibly study drug related adverse event. 13(37%) participants could not tolerate 100&#xa0;mg/day and underwent dose reduction to 60-80&#xa0;mg/day and 11(31%) participants discontinued study drug early due to drug related adverse events. The study concludes that following treatment with ibudilast up to 100&#xa0;mg/day in ALS participants, there were no significant reductions in (a) motor cortical glial activation measured by PBR28-PET SUVR over 12-24&#xa0;weeks or (b) CNS neuroaxonal loss, measured by serum NfL over 36-40&#xa0;weeks. Dose reductions and discontinuations due to treatment emergent adverse events were common at this dosage in ALS participants. Future pharmacokinetic and dose-finding studies of ibudilast would help better understand tolerability and target engagement in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babu</LastName><ForeName>Suma</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: SBABU@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hightower</LastName><ForeName>Baileigh G</ForeName><Initials>BG</Initials><AffiliationInfo><Affiliation>A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Z&#xfc;rcher</LastName><ForeName>Nicole R</ForeName><Initials>NR</Initials><AffiliationInfo><Affiliation>A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivis&#xe4;kk</LastName><ForeName>Pia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Alzheimer's Clinical and Translational Research Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>Chieh-En J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanders</LastName><ForeName>Danica L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robichaud</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banno</LastName><ForeName>Haruhiko</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Evora</LastName><ForeName>Armineuza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashokkumar</LastName><ForeName>Akshata</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pothier</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Department of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chew</LastName><ForeName>Sheena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dojillo</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medicinova Inc, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Kazuko</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medicinova Inc, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudesblatt</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>South Shore Neurologic Associates, Patchogue, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooker</LastName><ForeName>Jacob M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>A. A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atassi</LastName><ForeName>Nazem</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02714036</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>S10 OD023517</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Neuroimage Clin</MedlineTA><NlmUniqueID>101597070</NlmUniqueID><ISSNLinking>2213-1582</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011725">Pyridines</NameOfSubstance></Chemical><Chemical><RegistryNumber>M0TTH61XC5</RegistryNumber><NameOfSubstance UI="C038366">ibudilast</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker endpoint</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Ibudilast</Keyword><Keyword MajorTopicYN="N">MIF</Keyword><Keyword MajorTopicYN="N">Neurofilament</Keyword><Keyword MajorTopicYN="N">PBR28</Keyword><Keyword MajorTopicYN="N">Phase 1b</Keyword><Keyword MajorTopicYN="N">TNF-alpha</Keyword></KeywordList><CoiStatement>Nazem Atassi is an employee of Sanofi. Baileigh Hightower, Pia Kivis&#xe4;kk, Nicole R Z&#xfc;rcher, Chieh-En J Tseng, Danica L Sanders, Ashley Robichaud, Armineuza Evora, Akshata Ashokkumar and Lindsay Pothier report no COI related to this trial. Suma Babu reports research support from American Academy of Neurology, AANEM Foundation, The ALS Association., Muscular Dystrophy Association, Biogen Inc, Orion Corporation, Voyager Therapeutics and Novartis pharmaceuticals. James D. Berry has attended advisory boards at Alexion, Biogen and Clene Nanomedicine, has received research support from Alexion, Amylyx Therapeutics, Biogen, MT Pharma of America, Anelixis Therapeutics, Brainstorm Cell Therapeutics, Genentech, nQ Medical, ALS Finding a Cure, NINDS, Muscular Dystrophy Association, and ALS One. Sabrina Paganoni reports research grants from Amylyx Therapeutics, Revalesio Corporation, Ra Pharma/UCB, Biohaven Pharmaceuticals, Clene Nanomedicine, Prilenia Therapeutics, The ALS Association, the American Academy of Neurology, ALS Finding a Cure, the Salah Foundation, the Spastic Paraplegia Foundation and reports personal consulting fees for advisory panels from Orion Corporation. Sheena Chew is a full-time employee of Biogen and reports research support from the American Academy of Neurology and Biogen Inc. Haruhiko Banno reports research grant from Time Therapeutics and scientific advising fee from Sumitomo Dainippon Pharma. Jacob Hooker holds equity or stock options and/or has received income from Eikonizo Therapetics, Psy Therapeutics, Fuzionaire Diagnostics, and Delix Therapeutics. Merit Cudkowicz reports consulting fees from Biogen, Takeda, Sunovion, Cytokinetics, Immunitypharm, and Wave. Kazuko Matsuda is an employee of MediciNova. Joanna Dojillo is an employee of MediciNova.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>21</Day><Hour>5</Hour><Minute>57</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34016561</ArticleId><ArticleId IdType="pmc">PMC8102622</ArticleId><ArticleId IdType="doi">10.1016/j.nicl.2021.102672</ArticleId><ArticleId IdType="pii">S2213-1582(21)00116-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Albrecht D.S., Normandin M.D., Shcherbinin S., Wooten D.W., Schwarz A.J., Zurcher N.R. Pseudoreference regions for glial imaging with (11)C-PBR28: investigation in 2 clinical cohorts. J. Nucl. Med. 2018;59(1):107&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5750517</ArticleId><ArticleId IdType="pubmed">28818984</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Zurcher N.R., Loggia M.L., Cernasov P., Chonde D.B., Izquierdo Garcia D. Glial activation colocalizes with structural abnormalities in amyotrophic lateral sclerosis. Neurology. 2016;87(24):2554&#x2013;2561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5207001</ArticleId><ArticleId IdType="pubmed">27837005</ArticleId></ArticleIdList></Reference><Reference><Citation>Alshikho M.J., Zurcher N.R., Loggia M.L., Cernasov P., Reynolds B., Pijanowski O. Integrated magnetic resonance imaging and [(11) C]-PBR28 positron emission tomographic imaging in amyotrophic lateral sclerosis. Ann. Neurol. 2018;83(6):1186&#x2013;1197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105567</ArticleId><ArticleId IdType="pubmed">29740862</ArticleId></ArticleIdList></Reference><Reference><Citation>Babu S., Macklin E.A., Jackson K.E., Simpson E., Mahoney K., Yu H. Selection design phase II trial of high dosages of tamoxifen and creatine in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. Frontotemporal Degener. 2020;21(1&#x2013;2):15&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">31608711</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkar N., Boehringer A., Bowser R. Use of biomarkers in ALS drug development and clinical trials. Brain Res. 2015;14(1607):94&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4809521</ArticleId><ArticleId IdType="pubmed">25452025</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkhof F., Hulst H.E., Drulovic J., Uitdehaag B.M., Matsuda K., Landin R. Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology. 2010;74(13):1033&#x2013;1040.</Citation><ArticleIdList><ArticleId IdType="pubmed">20200338</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J., Toledo J.B., Van Deerlin V.M., Elman L., McCluskey L., Lee V.M. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 2012;7(6)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3375234</ArticleId><ArticleId IdType="pubmed">22720079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bridel C, van Wieringen WN, Zetterberg H, Tijms BM, Teunissen CE, and the NFL Group, et al. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA Neurol 2019 Jun 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6580449</ArticleId><ArticleId IdType="pubmed">31206160</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Miller R.G., Swash M., Munsat T.L. World federation of neurology research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2000;1(5):293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks B.R., Bravver E.K., Sanjak M.S., Bockenek W.L., Lindblom S.S., Lary C.L., Ranzinger L.H., Sturdivant A.N., Langford V.L., Holsten S.E., Ward A.L., Hillberry R., Wright A., Williamson T.A., Linville A.N., Lucas N.M., Brandon N.B., Dojillo J., Matsuda K., Iwaki Y., Graves D.C. Novel composite endpoint extended analysis during extension of Ibudilast Phase 1a/2b clinical trial better predicts post-wash-out survival. Platform Commun. Amyotroph. Lateral Scler. Frontotemporal Degener. 2018;19(sup1):1&#x2013;84. doi: 10.1080/21678421.2018.1510202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1510202</ArticleId></ArticleIdList></Reference><Reference><Citation>Canto E, Barro C, Zhao C, Caillier SJ, Michalak Z, Bove R, et al. Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years. JAMA Neurol 2019 Aug 12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6692664</ArticleId><ArticleId IdType="pubmed">31403661</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum J.M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III) J. Neurol. Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang H., Ying Z., Gao Q. Ibudilast enhances the clearance of SOD1 and TDP-43 aggregates through TFEB-mediated autophagy and lysosomal biogenesis: The new molecular mechanism of ibudilast and its implication for neuroprotective therapy. Biochem. Biophys. Res. Commun. 2020;526(1):231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pubmed">32204915</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho Y., Crichlow G.V., Vermeire J.J., Leng L., Du X., Hodsdon M.E. Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast. Proc. Natl. Acad. Sci. USA. 2010;107(25):11313&#x2013;11318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2895110</ArticleId><ArticleId IdType="pubmed">20534506</ArticleId></ArticleIdList></Reference><Reference><Citation>Coalition Adaptive Platform Trials. Adaptive platform trials: definition, design, conduct and reporting considerations. Nat Rev Drug Discov. 2019;18(10):797&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">31462747</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox G.M., Kithcart A.P., Pitt D., Guan Z., Alexander J., Williams J.L. Macrophage migration inhibitory factor potentiates autoimmune-mediated neuroinflammation. J. Immunol. 2013;191(3):1043&#x2013;1054.</Citation><ArticleIdList><ArticleId IdType="pubmed">23797673</ArticleId></ArticleIdList></Reference><Reference><Citation>DeYoung D.Z., Heinzerling K.G., Swanson A.N., Tsuang J., Furst B.A., Yi Y. Safety of intravenous methamphetamine administration during ibudilast treatment. J. Clin. Psychopharmacol. 2016;36(4):347&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4927401</ArticleId><ArticleId IdType="pubmed">27269956</ArticleId></ArticleIdList></Reference><Reference><Citation>Downer OM, Marcus REG, Zurcher NR, Hooker JM. Tracing the History of the Human Translocator Protein to Recent Neurodegenerative and Psychiatric Imaging. ACS Chem Neurosci 2020 Jul 23.</Citation><ArticleIdList><ArticleId IdType="pubmed">32662626</ArticleId></ArticleIdList></Reference><Reference><Citation>Fox R.J., Coffey C.S., Conwit R., Cudkowicz M.E., Gleason T., Goodman A. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N. Engl. J. Med. 2018;379(9):846&#x2013;855.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6172944</ArticleId><ArticleId IdType="pubmed">30157388</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T., Sakoda S., Fujimura H., Yanagihara T. Ibudilast, a phosphodiesterase inhibitor, ameliorates experimental autoimmune encephalomyelitis in Dark August rats. J. Neuroimmunol. 1999;95(1&#x2013;2):35&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">10229113</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita M., Imaizumi M., Zoghbi S.S., Fujimura Y., Farris A.G., Suhara T. Kinetic analysis in healthy humans of a novel positron emission tomography radioligand to image the peripheral benzodiazepine receptor, a potential biomarker for inflammation. Neuroimage. 2008;40(1):43&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2265774</ArticleId><ArticleId IdType="pubmed">18093844</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson L.C., Hastings S.F., McPhee I., Clayton R.A., Darroch C.E., Mackenzie A. The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol. 2006;538(1&#x2013;3):39&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">16674936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, et al. Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF). Sci Rep 2019 Feb 27;9(1):2905-019-39427-4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6393433</ArticleId><ArticleId IdType="pubmed">30814573</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang F, Zhu Y, Hsiao-Nakamoto J, Tang X, Dugas JC, Moscovitch-Lopatin M, et al. Longitudinal biomarkers in amyotrophic lateral sclerosis. Ann Clin Transl Neurol 2020 Jun 9.</Citation></Reference><Reference><Citation>Jucaite A., Svenningsson P., Rinne J.O., Cselenyi Z., Varnas K., Johnstrom P. Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain. 2015;138(Pt 9):2687&#x2013;2700.</Citation><ArticleIdList><ArticleId IdType="pubmed">26137956</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P., Thompson J.L., Levy G., Buchsbaum R., Shefner J., Krivickas L.S. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009;66(2):235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2854625</ArticleId><ArticleId IdType="pubmed">19743457</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshavan A., Heslegrave A., Zetterberg H., Schott J.M. Stability of blood-based biomarkers of Alzheimer's disease over multiple freeze-thaw cycles. Alzheimers Dement (Amst) 2018;2(10):448&#x2013;451.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131984</ArticleId><ArticleId IdType="pubmed">30211292</ArticleId></ArticleIdList></Reference><Reference><Citation>Knudson R.J., Lebowitz M.D., Holberg C.J., Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am. Rev. Respir. Dis. 1983;127(6):725&#x2013;734.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J., Barro C., Andreasson U., Derfuss T., Lindberg R., Sandelius A. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin. Chem. Lab. Med. 2016;54(10):1655&#x2013;1661.</Citation><ArticleIdList><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J., Menon P., Byth K., Morrison S., Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J. Neurol. Neurosurg. Psychiatry. 2016;87(6):628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C.H., Macdonald-Wallis C., Gray E., Pearce N., Petzold A., Norgren N. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T., Cudkowicz M., Shaw P.J., Andersen P.M., Atassi N., Bucelli R.C. Phase 1&#x2013;2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizrahi R., Rusjan P.M., Kennedy J., Pollock B., Mulsant B., Suridjan I. Translocator protein (18 kDa) polymorphism (rs6971) explains in-vivo brain binding affinity of the PET radioligand [(18)F]-FEPPA. J. Cereb. Blood Flow Metab. 2012;32(6):968&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3367231</ArticleId><ArticleId IdType="pubmed">22472607</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno T., Kurotani T., Komatsu Y., Kawanokuchi J., Kato H., Mitsuma N. Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia. Neuropharmacology. 2004;46(3):404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pubmed">14975696</ArticleId></ArticleIdList></Reference><Reference><Citation>Novakova L., Zetterberg H., Sundstrom P., Axelsson M., Khademi M., Gunnarsson M. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology. 2017;89(22):2230&#x2013;2237.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5705244</ArticleId><ArticleId IdType="pubmed">29079686</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen D.R., Yeo A.J., Gunn R.N., Song K., Wadsworth G., Lewis A. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J. Cereb. Blood Flow Metab. 2012;32(1):1&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3323305</ArticleId><ArticleId IdType="pubmed">22008728</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S., Alshikho M.J., Luppino S., Chan J., Pothier L., Schoenfeld D. A pilot trial of RNS60 in amyotrophic lateral sclerosis. Muscle Nerve. 2019;59(3):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6379136</ArticleId><ArticleId IdType="pubmed">30458059</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J.J.H., Harari O., Dron L., Lester R.T., Thorlund K., Mills E.J. An overview of platform trials with a checklist for clinical readers. J. Clin. Epidemiol. 2020;13(125):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">32416336</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmar A., Zurcher N.R., Hooker J.M. Time Will Tell the Utility of Biomarkers. ACS Chem. Neurosci. 2020;11(12):1692&#x2013;1695.</Citation><ArticleIdList><ArticleId IdType="pubmed">32463674</ArticleId></ArticleIdList></Reference><Reference><Citation>Pascuzzi R.M., Shefner J., Chappell A.S., Bjerke J.S., Tamura R., Chaudhry V. A phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(3):266&#x2013;271.</Citation><ArticleIdList><ArticleId IdType="pubmed">19961264</ArticleId></ArticleIdList></Reference><Reference><Citation>Poesen K., Van Damme P. Diagnostic and prognostic performance of neurofilaments in ALS. Front. Neurol. 2019;18(9):1167.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6345692</ArticleId><ArticleId IdType="pubmed">30713520</ArticleId></ArticleIdList></Reference><Reference><Citation>Proudfoot M, Jones A, Talbot K, Al-Chalabi A, Turner MR. The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotroph Lateral Scler Frontotemporal Degener 2016 Jul-Aug;17(5-6):414-425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4950444</ArticleId><ArticleId IdType="pubmed">26864085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray L.A., Bujarski S., Shoptaw S., Roche D.J., Heinzerling K., Miotto K. Development of the neuroimmune modulator ibudilast for the treatment of alcoholism: a randomized, placebo-controlled, human laboratory trial. Neuropsychopharmacology. 2017;42(9):1776&#x2013;1788.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5520778</ArticleId><ArticleId IdType="pubmed">28091532</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanftner L.M., Gibbons J.A., Gross M.I., Suzuki B.M., Gaeta F.C., Johnson K.W. Cross-species comparisons of the pharmacokinetics of ibudilast. Xenobiotica. 2009;39(12):964&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">19925385</ArticleId></ArticleIdList></Reference><Reference><Citation>Sejbaek T., Nielsen H.H., Penner N., Plavina T., Mendoza J.P., Martin N.A. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J. Neurol. Neurosurg. Psychiatry. 2019;90(12):1324&#x2013;1330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6902070</ArticleId><ArticleId IdType="pubmed">31611264</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J.M., Liu D., Leitner M.L., Schoenfeld D., Johns D.R., Ferguson T. Quantitative strength testing in ALS clinical trials. Neurology. 2016;87(6):617&#x2013;624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzumura A., Ito A., Yoshikawa M., Sawada M. Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res. 1999;837(1&#x2013;2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">10434004</ArticleId></ArticleIdList></Reference><Reference><Citation>Zach N., Ennist D.L., Taylor A.A., Alon H., Sherman A., Kueffner R. Being PRO-ACTive: what can a clinical trial database reveal about ALS? Neurotherapeutics. 2015;12(2):417&#x2013;423.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404433</ArticleId><ArticleId IdType="pubmed">25613183</ArticleId></ArticleIdList></Reference><Reference><Citation>Zurcher N.R., Loggia M.L., Lawson R., Chonde D.B., Izquierdo-Garcia D., Yasek J.E. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;19(7):409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4310932</ArticleId><ArticleId IdType="pubmed">25685708</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>